FDA APPROVES CADILA'S GENERIC PAXIL

Cadila Healthcare announced it has received approval from the FDA to market its generic version of GlaxoSmithKline's (GSK) Paxil in strengths of 10, 20, 30 and 40 mg.

Global sales of Paxil (paroxetine) tablets are estimated at $850 million, according to Cadila. The company will market paroxetine through its U.S. subsidiary, Zydus Pharmaceuticals.

Paxil is approved for the treatment of depression, generalized anxiety disorder, social anxiety disorder, panic disorder, obsessive-compulsive disorder and posttraumatic stress disorder in adults, according to GSK.

This is the 19th of Cadila's abbreviated new drug applications to receive FDA approval.